knowledge -WSS

knowledge

author：comprehensive 2025-10-01 00:59:16 - browse：35

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Curing rare childhood diseases will falter unless Congress steps up

focus

WSS

WATCH: Why do our ears pop?

Abridge raises $150m as clinical notes automation market heats up

Teladoc has a new CEO, but challenges remain the same

California wildfire smoke linked to 52,000 early deaths, study says

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

MD Anderson's Padmanee Sharma responds to research credit suit

focus

knowledge

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Deposition: Sackler embraced plan to conceal OxyContin’s strength

FDA approval of Sarepta Duchenne genetic therapy gives me hope

ALS patient reclaims some autonomy thanks to wearable 'robot'

Psychedelics group wrestles with new pharma identity

Obamacare plans could cover weight loss drugs

Apple is now the first public company to be valued at $3 trillion

As AI regulations shape up, health tech startups beg for clarity

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Coercive sterilizations revealed by STAT prompt outrage

hotspot

Lilly's Alzheimer's drug donanemab backed by FDA advisers

A new drug could help frostbite victims avoid its ravages

Cigna wins case to block Amy Bricker's move to CVS

In 'major milestone,' FDA approves first cell therapy for solid tumors

Medical device trials still don't enroll enough women, study finds

Pharma companies must ensure equitable access to obesity drugs

knowledge

focus

explore

leisure time